


=> d ibib abs hitstr l11 16

L11 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2000:900666 HCAPLUS
 DOCUMENT NUMBER: 134:56968
 TITLE: preparation of statine-derived tetrapeptides as
inhibitors of β -secretase
 INVENTOR(S): John, Varghese; Tung, Jay; Fang,
 Lawrence; Mamo, Shumeye S.
 PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2000077030 | A1 | 20001221 | WO 2000-US16643 | 20000615 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2376420 | AA | 20001221 | CA 2000-2376420 | 20000615 |
| EP 1192177 | A1 | 20020403 | EP 2000-941491 | 20000615 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2003502342 | T2 | 20030121 | JP 2001-503887 | 20000615 |
| PRIORITY APPLN. INFO.: US 1999-139173P P 19990615 | | | | |
| WO 2000-US16643 W 20000615 | | | | |
| AB Statine-derived peptides ACONHCH(R4) CONHCH(R3) CONHCH(R2) CH(OH) CH ₂ CONHCH(R1) COB [A = straight or branched chain alkanoxy or alkenoxy of 1-5 carbons, (un)substituted aryl or arylalkyl; R1 = H, C1-C5 alkyl; R2 = i-Pr, i-Bu, or Ph (un)substituted with H, OH, C1-C2 alkyl, Ph, halogen, etc.; R3 = Ph, C1-C5 alkyl, or 2-methylthioethyl; R4 = i-Pr, sec-Bu, or i-Pr; B = hydroxy or various N-attached groups, e.g., 3,5-, 3,4-, 2,4-, 2,5-dicarboxycyclohexylamine or 4-aminobenzoic acid] were prepared as inhibitors of β-secretase . Thus, Boc-L-Val-L-Met-L-Sta-L-Val-OMe (Boc = tert-butoxycarbonyl, Sta = statine residue) was prepared by peptide coupling in solution and assayed for β-secretase inhibition (IC ₅₀ > 200 μ M). | | | | |
| IT 313683-21-5P 313683-26-0P 313683-27-1P 313683-31-7P | | | | |
| RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of statine-derived tetrapeptides as inhibitors of β-secretase) | | | | |
| RN 313683-21-5 HCAPLUS | | | | |
| CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-, methyl ester (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.



RN 313683-26-0 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(4-methoxy-4-oxobutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-27-1 HCAPLUS

CN β -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-L-valyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-31-7 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[(4-carboxyphenyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT 313683-22-6P 313683-23-7P 313683-24-8P
313683-25-9P 313683-28-2P 313683-29-3P
313683-30-6P 313683-32-8P 313683-33-9P
313683-34-0P 313683-35-1P 313683-36-2P
313683-37-3P 313683-38-4P 313683-39-5P
313683-40-8P 313683-41-9P 313683-42-0P
313683-43-1P 313683-44-2P 313683-45-3P
313683-46-4P 313683-47-5P 313683-48-6P
313683-49-7P 313683-50-0P 313683-51-1P
313683-52-2P 313683-53-3P 313991-25-2P
313991-27-4P 313991-29-6P 313991-31-0P
313991-33-2P 313991-35-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of statine-derived tetrapeptides as inhibitors of

β - secretase)

RN 313683-22-6 HCAPLUS

CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-23-7 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-24-8 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-pentyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-25-9 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-28-2 HCAPLUS


CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(3-carboxypropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313683-29-3 HCAPLUS
 CN β -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-
 (3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-L-valyl- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 313683-30-6 HCAPLUS
 CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-
 4-amino-3-hydroxy-6-methylheptanoyl-N-[(5-carboxy-2-thiazolyl)methyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-32-8 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(4-pyridinylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-33-9 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[[4-(carboxymethoxy)phenyl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-34-0 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[(3-carboxyphenyl)methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 313683-35-1 HCAPLUS

CN L-Glutamamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-36-2 HCAPLUS

CN Cyclopropanecarboxylic acid, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-L-valyl-1-amino-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-37-3 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(tetrahydro-2-oxo-3-furanyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-38-4 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(4-hydroxybutyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 313683-39-5 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(3-carboxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-40-8 HCAPLUS

CN L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-N-[(1S,2S)-4-[[[(1S)-1-[[4-(carboxymethyl)-1-piperidinyl]carbonyl]-2-methylpropyl]amino]-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-41-9 HCAPLUS

CN L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-N-[(1S,2S)-4-[[[(1S)-1-[[4-(ethoxycarbonyl)-1-piperazinyl]carbonyl]-2-methylpropyl]amino]-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-42-0 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[2-(acetylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-43-1 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-44-2 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[4-(aminocarbonyl)phenyl)methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-45-3 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[(4-carboxyphenyl)methyl]-N-methyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-46-4 HCAPLUS

CN L-Glutamic acid, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-47-5 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[1-(4-carboxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-48-6 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-49-7 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(3-carboxycyclohexyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-50-0 HCAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-L-valyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313683-51-1 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[2-(4-hydroxy-3-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 313683-52-2 HCAPLUS

CN L-Valinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-2-phenylglycyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[(4-carboxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— Ph

RN 313683-53-3 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-2-phenylglycyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[(4-carboxyphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313991-25-2 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(4-carboxycyclohexyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313991-27-4 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(3,5-dicarboxycyclohexyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 313991-29-6 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(2,5-dicarboxycyclohexyl)-(9CI)
(CA INDEX NAME)


Absolute stereochemistry. .



RN 313991-31-0 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[4-(carboxymethyl)cyclohexyl]-(9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 313991-33-2 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-L-methionyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-(3,4-dicarboxycyclohexyl)-(9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 313991-35-4 HCAPLUS

CN L-Valinamide, N-acetyl-L-valyl-(2S)-2-phenylglycyl-4-amino-2,4,5-trideoxy-5-phenyl-L-threo-pentonoyl-N-[(4-hydroxyphenyl)methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 158736-49-3, β - Secretase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of statine-derived tetrapeptides as inhibitors of β - secretase)

RN 158736-49-3 HCAPLUS

CN β -Secretase (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 56-91-7 75-04-7, Ethylamine, reactions 99-27-4
100-46-9, Benzylamine, reactions 110-58-7, 1-Pentanamine
369-53-9 371-40-4, 1-Amino-4-fluorobenzene
1001-53-2 1126-09-6 2013-17-4
3251-07-8, Methyl 4-aminobutanoate 4138-35-6, Methyl
3-aminopropanoate 4518-10-9, Methyl 3-aminobenzoate
5372-81-6 6525-53-7 6971-44-4, Methyl
4-aminomethylpyridine 18469-52-8 26682-99-5
42042-68-2, Methyl 4-aminobutanol 49607-15-0
51832-31-6 58521-49-6, Boc-statine 72784-43-1
74165-73-4 87091-29-0 93071-65-9, Methyl
3-aminomethylbenzoate 105114-21-4 113023-73-7
132224-97-6 168986-49-0 175867-59-1
313683-54-4 313683-56-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of statine-derived tetrapeptides as inhibitors of β - secretase)

RN 56-91-7 HCAPLUS

CN Benzoic acid, 4-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 75-04-7 HCAPLUS


CN Ethanamine (9CI) (CA INDEX NAME)




RN 99-27-4 HCAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-amino-, dimethyl ester (9CI) (CA INDEX


NAME)




RN 100-46-9 HCAPLUS
 CN Benzenemethanamine (9CI) (CA INDEX NAME)




RN 110-58-7 HCAPLUS
 CN 1-Pentanamine (9CI) (CA INDEX NAME)




RN 369-53-9 HCAPLUS
 CN Benzamide, 4-(aminomethyl)- (9CI) (CA INDEX NAME)




RN 371-40-4 HCAPLUS
 CN Benzenamine, 4-fluoro- (9CI) (CA INDEX NAME)



RN 1001-53-2 HCAPLUS
 CN Acetamide, N-(2-aminoethyl)- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 1126-09-6 HCAPLUS
CN 4-Piperidinecarboxylic acid, ethyl ester (9CI) (CA INDEX NAME)




RN 2013-17-4 HCAPLUS
CN Pentanediamide, 2-amino-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 3251-07-8 HCAPLUS
CN Butanoic acid, 4-amino-, methyl ester (9CI) (CA INDEX NAME)



RN 4138-35-6 HCAPLUS
CN β -Alanine, methyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 4518-10-9 HCAPLUS
CN Benzoic acid, 3-amino-, methyl ester (9CI) (CA INDEX NAME)



RN 5372-81-6 HCAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-amino-, dimethyl ester (9CI) (CA INDEX NAME)


NAME)



RN 6525-53-7 HCAPLUS


CN L-Glutamic acid, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 6971-44-4 HCAPLUS

CN 4-Pyridinemethanamine, N-methyl- (9CI) (CA INDEX NAME)




RN 18469-52-8 HCAPLUS

CN Benzoic acid, 4-(aminomethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 26682-99-5 HCAPLUS


CN Benzeneacetic acid, α-amino-, methyl ester (9CI) (CA INDEX NAME)




RN 42042-68-2 HCAPLUS
 CN 1-Butanol, 4-(methylamino)- (6CI, 7CI, 9CI) (CA INDEX NAME)



RN 49607-15-0 HCAPLUS
 CN Phenol, 4-(2-aminoethyl)-2-nitro- (9CI) (CA INDEX NAME)




RN 51832-31-6 HCAPLUS
 CN 1,2-Benzenedicarboxylic acid, 4-amino-, dimethyl ester (9CI) (CA INDEX NAME)




RN 58521-49-6 HCAPLUS
 CN Heptanoic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-hydroxy-6-methyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 72784-43-1 HCAPLUS
 CN Cyclopropanecarboxylic acid, 1-amino-, methyl ester (9CI) (CA INDEX NAME)




RN 74165-73-4 HCAPLUS

CN 1H-Inden-2-ol, 1-amino-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 87091-29-0 HCAPLUS

CN Cyclohexanecarboxylic acid, 3-amino-, methyl ester (9CI) (CA INDEX NAME)




RN 93071-65-9 HCAPLUS

CN Benzoic acid, 3-(aminomethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 105114-21-4 HCAPLUS

CN Pentonic acid, 4-amino-2,4,5-trideoxy-5-phenyl- (9CI) (CA INDEX NAME)




RN 113023-73-7 HCAPLUS


CN Benzoic acid, 4-(1-bromoethyl)- (9CI) (CA INDEX NAME)




RN 132224-97-6 HCAPLUS
 CN Acetic acid, [4-(aminomethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 168986-49-0 HCAPLUS
 CN 4-Piperidineacetic acid, methyl ester (9CI) (CA INDEX NAME)




RN 175867-59-1 HCAPLUS
 CN Cyclohexanecarboxylic acid, 4-amino-, methyl ester (9CI) (CA INDEX NAME)



RN 313683-54-4 HCAPLUS
 CN 5-Thiazolecarboxylic acid, 2-(aminomethyl)-, methyl ester (9CI) (CA INDEX NAME),




RN 313683-56-6 HCAPLUS
CN Cyclohexaneacetic acid, 4-amino-, methyl ester (9CI) (CA INDEX NAME)




IT 2417-75-6P 313683-55-5P 313683-57-7P
313683-58-8P 313683-59-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of statine-derived tetrapeptides as **inhibitors** of
 β - **secretase**)


RN 2417-75-6 HCAPLUS
CN 1-Naphthalenecarboxylic acid, 4-(bromomethyl)-, methyl ester (9CI) (CA
INDEX NAME)




RN 313683-55-5 HCAPLUS
CN 1,3-Cyclohexanedicarboxylic acid, 5-amino- (9CI) (CA INDEX NAME)




RN 313683-57-7 HCAPLUS
CN 1,3-Cyclohexanedicarboxylic acid, 5-amino-, dimethyl ester (9CI) (CA
INDEX NAME)



RN 313683-58-8 HCAPLUS
CN 1-Naphthalenecarboxylic acid, 4-(azidomethyl)-, methyl ester (9CI) (CA
INDEX NAME)



RN 313683-59-9 HCAPLUS
CN 1-Naphthalenecarboxylic acid, 4-(aminomethyl)-, methyl ester (9CI) (CA
INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.99

44.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.46

-1.46

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 15:12:41 ON 03 FEB 2005